Experience EyeArt

Immediate, Fully-automated, On-site Diabetic Retinopathy Screening


* Products were supported by Award numbers R44EB013585, R42TR000377, R44TR000377, R43EY024848, R43EY025984, SB1EY027241, and R43EY028081  from the National Institutes of Health (NIH). The content is solely the responsibility of Eyenuk, Inc. and does not necessarily represent the official views of NIH.

** The devices are covered by one or more of the following US patents and their foreign counterparts: 8879813, 8885901, 9002085, and 9008391. Additional patents are pending.

EyeArt for DR detection has US FDA clearance, CE marking as a class IIb medical device in the European Union, and a Health Canada license.

EyeMark™, EyeReadUWF™, and Eyenuk products for AMD and Glaucoma have not yet been cleared for sales in any region.